Tirzepatide Meds

Tirzepatide References — Full Citation List

Tirzepatide references — full citation list

The numbered references below correspond to inline citations [N] across all pages on this site. Each citation is sourced from the corpus used to build this site; DOIs and PubMed URLs are included where available for verification. Tirzepatide references are also available in machine-readable form at /llms.txt and /llms-full.txt.

  1. Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018. ↗
  2. Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021. ↗
  3. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. ↗
  4. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. ↗
  5. Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020. ↗
  6. Zeng Q, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023. ↗
  7. U.S. Food and Drug Administration. Tirzepatide injection prescribing information (FDA label, type 2 diabetes indication). FDA Drugs@FDA. 2022. ↗
  8. Farzam K, Patel P. Tirzepatide (StatPearls). StatPearls [Internet], NCBI Bookshelf. 2024. ↗
  9. et al. Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes. touchREV Endocrinol / Eur Endocrinol. 2022. ↗
  10. Pankratz J, et al. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT Pharmacometrics Syst Pharmacol. 2024. ↗
  11. Qaseem A, et al. Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026). Ann Intern Med. 2026. ↗
  12. Nauck MA, et al. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026. ↗
  13. Safwan M, et al. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis. Ann Saudi Med. 2025. ↗
  14. Shen P, et al. Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis. PLoS One. 2026. ↗
  15. Almansour HA, et al. Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025). Healthcare (Basel). 2025. ↗
  16. Gong J, et al. Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis. J Diabetes Investig. 2025. ↗
  17. Galli M, et al. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol. 2025. ↗
  18. Nassar M, et al. Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: A propensity matched global federated TriNetX database-based retrospective cohort study. Diabetes Metab Syndr. 2024. ↗
  19. Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025. ↗
  20. Batsis JA, et al. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review. Ann Intern Med. 2026. ↗
  21. Locatelli JC, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024. ↗
  22. Berg S, et al. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis. Obes Rev. 2025. ↗
  23. Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. ↗
  24. Horn DB, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Intern Med. 2026. ↗
  25. Jalleh RJ, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab. 2024. ↗
  26. et al. Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. Cureus. 2025. ↗
  27. Kunutsor SK, et al. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review. Drugs. 2026. ↗
  28. Urva S, et al. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clin Pharmacokinet. 2022. ↗
  29. Rasouli N, et al. Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials. Diabetes Ther. 2025. ↗